$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

공황장애의 임상적 특성과 Brain-Derived Neurotrophic Factor 농도와의 관계
Associations between Clinical Characteristics and Plasma BDNF Levels of Panic Disorder 원문보기

Anxiety and mood = 대한불안의학회지, v.11 no.2, 2015년, pp.129 - 135  

황인호 (전북대학교병원 정신건강의학과) ,  박종일 (전북대학교병원 정신건강의학과) ,  양종철 (전북대학교병원 정신건강의학과)

Abstract AI-Helper 아이콘AI-Helper

Objective : Brain-derived neurotrophic factor (BDNF) is implicated in the pathophysiology of several neuropsychiatric disorders. However, there are few studies on BDNF of panic disorder. In this study, we investigated plasma BDNF levels in patients with panic disorder, and evaluated whether there ar...

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

  • 본 연구는 공황장애 환자를 대상으로 혈장 BDNF 농도를 측정한 후, 공황장애의 임상적 특징과 BDNF 농도와의 관련성을 조사함으로서 공황장애의 병태생리에 대한 기초자료를 얻고자 함을 목적으로 하였다.
본문요약 정보가 도움이 되었나요?

참고문헌 (62)

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, 4th ed. Washington: American Psychiatric Publishing;1994. p.430-443. 

  2. Hirschfeld RM. Panic Disorder: Diagnosis, epidemiology, and clinical course. J Clin Psychiatry 1996;57:3-8. 

  3. Sadock BJ, Sadock VA: Panic disorder and agoraphobia. In: Kaplan and Sadock's Synopsis of Psychiatry. 9th ed. Baltimore: Williams and Wilkins;2003. p. 599-609. 

  4. Rosenbaum JF, Pollack MH, Pollock RA: Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry 1996;57 Suppl 10:44-48: discussion 49-50. 

  5. Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. AMJ Psychiatry 1994;151:413-420 

  6. Eaton W W, Keyl PM: The epidemiology of panic. In: Panic Disorder: Clinical, Biological, and Treatment Aspects. New York: John Wiley & Sons, Inc. ; 1995.p. 50-65. 

  7. Coryell W, Noyes R, Clancy J. Excess mortality in panic disorder. A comparison with primary unipolar depression. Arch Gen Psychiatry 1982;39:701-703. 

  8. Coryell W, Noyes R Jr, House JD. Mortality among outpatients with anxiety disorders. Am J Psychiatry 1986;143:508-510. 

  9. Rosen JB. The neurobiology of conditioned and unconditioned fear: a neurobehavioral system analysis of the amygdala. Behav Cogn Neurosci Rev 2004;3:23-41. 

  10. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505. 

  11. Nesse RM, Cameron OG, Curtis GC, Mccann DS, Huber-Smith MJ. Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 1984;41:771-776. 

  12. Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacol 2006;31: 1-11. 

  13. Kent JM, Coplan JD, Gorman JM. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 1998; 44:812-824. 

  14. Bremner JD, Innis RB, White T, Fujita M, Silbersweig d, Goddard AW, et al. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000;47:96-106. 

  15. Malizia AL, Cunningham VJ, Bell CJ, Liddle PE, Jones T, Nutt DJ. Decreased brain GABA (A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998;55:715-720. 

  16. Abelson JL, Khan S, Liberzon I, Young EA. HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress Anxiety 2007;24:66-76. 

  17. Lewin GR, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci 1996;19:289-317. 

  18. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS. Neurotrophic factors: from molecule to man. Trends Neurosci 1994;17:182-190. 

  19. Numata S, Veno S, Iga J, Yamauchi K, Hongwei S, Ohta K, et al. Brain-derived neutrotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 2006;401:1-5. 

  20. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 2009;466:139-143. 

  21. Shim SH, Hwangbo Y, Kwon YJ, Jeong HY, Lee BH, Lee HJ, et al. Increased levels of plasma brain-derived neurotrophic factor (BONF) in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1824-1828. 

  22. Fluimura H, Altar Ca, Chen R, Nakamura T, Nakabashi T, Kambayashi, et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002;87:728-734. 

  23. Rosenfeld RD, Zeni L, Haniu M, Talvenheimo J, Radka SF, Bennett L, et al. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr Purif 1995;6:465-471. 

  24. Pan W, Banks WA, Fasold MB. Bluth J, Kastin AJ. Transport of brainderived neurotrophic factor across the blood-brain barrier. Neuropharmacol 1998;37: 1553-1561. 

  25. Poduslo JF, Curran GL. Permeability at the blood-brain and blood nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 1996;36:280-286. 

  26. Kobayashi K, Shimizu E. Hashimoto K. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: As a biological predictor of response to group cognitive behavioral therapy. Prog neuro-psychopharmacol Biol Psychiatry 2005;29:658-663. 

  27. Lam P, Cheng CY, Hong CJ, Tsai SJ. Association study of a BrainDerived Neurotrophic Factor (Val 66Met) Genetic polymorphism and Panic disorder. Neuropsychobiol 2004;49:178-181. 

  28. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research;1995. 

  29. Yi JS, Bae SO, Ahn YM, Park DB, Noh KS, Shin HK, et al. Validity and Reliability of the Korean Version of the Hamilton Depression Rating Scale (K-HDRS). J Korean Neuropsychiatr Assoc 2005;44:456-465. 

  30. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders-Non-Patient Edition (SCIDI/NP), version 2.0. New York, New York State Psychiatric Institute, Biometrics Research;1996. 

  31. Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, et al. WCA Recommendations for the Long-Term Treatment of Panic Disorder. CNS Spectrums 2003;8:S17-S30. 

  32. Fiammetta C. The psychological development of panic disorder: implications for neurobiology and treatment. Rev Bras Psiquiatr 2012;34:S09-S31 

  33. Holmes TH, Rahe RH. The social readjustment rating scale. Journal of Psychosomatic Research 1967;11(2):213-218. 

  34. Hong KE, Jeong DU. Construction of Korean 'social readjustment rating scale' -A methodological study-. Journal of Korean Neuropsychiatric Association 1982;21: 123-136. 

  35. Beck AT, Steer RA, Brown G K. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation;1996. 

  36. Spielberger C. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA; 1983. 

  37. Kim JB. Development of the Korean Version of the Panic Disorder Severity Scale. Korean J Psychopathol 2001;10:140-151. 

  38. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychology 1959;32:50-55. 

  39. Radka SF, Holst PA, Fritsche M, Altar CA. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res 1996;709:122-301. 

  40. Gold SM, Schulz KH, Hartmann S, Mladek M, Lang UE, Hellweg R, et al. Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol 2003;138:99-105. 

  41. Angelucci F, Oliviero A, Pilato F, Saturno E, Dileone M, Versace V, et al. Transcranial magnetic stimulation and BDNF plasma levels in amyotrophic lateral sclerosis. Neuroreport 2004;15:717-720. 

  42. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005;57:1068-1072. 

  43. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997;42:290-295. 

  44. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153:1313-1317. 

  45. Lee BH, Kim YK. Reduced platelet BDNF level in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:849-853. 

  46. Lee BH, Kim YK. BDNF mRNA in peripheral blood mononuclear cells of depressive patients with or without attempted suicide. Poster presentation in The Korean Neuropsychiatric Association The 50th Annual Meeting;2007. 

  47. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004;27:589-594. 

  48. Brindle PK, Montminy MR. The CREB family of transcription activators. Curr Opin Genet Dev 1992:2:199-204. 

  49. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365-2372. 

  50. Asberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 1997;836:158-181. 

  51. Kasper S, Resinger E. Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2001;11:307-321. 

  52. Van Der Kolk BA. The psychobiology and psychopharmacology of PTSD. Hum Psychopharmacol 2001;16:S49-S64. 

  53. Baldwin DS, Waldman S, Allqulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. lnt J Neuropsychopharmacol 2011;14:697-710. 

  54. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 1992;59:99-106. 

  55. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995;15:1768-1777. 

  56. Marmigere F, Givalois L, Rage F, Arancibia S, Tapia-Arancibia L. Rapid induction of BDNF expression in the hippocampus during immobilization stress challenge in adult rats. Hippocampus 2003;13:646-655. 

  57. Molteni R, Calabrese F, Cattaneo A, Mancini M, Gennarelli M, Racagni G, et al. Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine. Neuropsychopharmacol 2009;34:1523-1532. 

  58. Lee BH, Kim YK. The Meaning of BDNF Level Measured in Blood of Depressed Patients. J Korean Neuropsyehiatr Assoc 2009;48:203-206 

  59. Murakamia S, Imbea H, Morikawa Y, Kubob C, Senbaa E. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. Neuroscience Research 2005;53: 129-139. 

  60. Ziegenhorn AA, Schulte-Herbruggen O, Danker-Hopfe H, Malbranc M, Hartung HD, Anders D, et al. Serum neurotrophins: a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 2007;28:1436-1445. 

  61. Trajkovska V, Marcussen AB, Vinberg M, Hartvig P, Aznar S, Knudsen GM. Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull 2007;73:143 

  62. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol. Aging 2005;26:115-123. 

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로